



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Brian D. FOLLSTAD

Docket No.: 3374-A

Serial No.: 10/620,064

Group Art Unit No.: 1651

Filed: July 15, 2003

Examiner: Lankford Jr., Leon B.

For: METHODS AND MEDIA FOR CONTROLLING SIALYLATION
OF PROTEINS PRODUCED BY MAMMALIAN CELLS

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicant submits a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

Applicants make no determination of relevancy with respect to the reference(s) submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of the reference(s).

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,
- whichever occurs first.

STATEMENT OR FEE

Accompanying this transmittal is:

- A ☐ a statement as specified in 37 CFR 1.97(e):

STATEMENT

I, the person(s) signing below state:



that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(1).

OR

- ☐ that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(2).

OR

- B. ☒ the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$180.00).


Applicant(s) request(s) consideration of this information and passage of the application to issue.

FEE PAYMENT

Please charge Deposit Account No. 09-0089 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,



Rosemary Sweeney
Attorney/Agent for Applicant
Registration No.: 52,264
Phone: (206) 265-7817
Date: December 20, 2006

Please send all future correspondence to:

22932

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, Washington 98119-3105
(206) 265-7000



Sheet 1 Of 1

Modified Form PTO-1449

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

3374-A

Serial No.

10/620,064

Applicant

Brian D. Follstad

Filing Date

7/15/03

Group

1651

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
6-292592	10.21.1994	JP			Yes

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

	Baker, K. N. et al., "Metabolic control of recombinant protein <i>N</i> -glycan processing in NSO and CHO cells," <i>Biotechnol Bioeng</i> 73:188-202, 2001.
	Ghannoum, M. A. et al., "In vitro determination of optimal antifungal combinations against <i>Cryptococcus neoformans</i> and <i>Candida albicans</i> ," <i>Antimicrob Agents Chemother</i> 39(11):2459-2465, 1995.
	Hills, A. E. et al., "Metabolic control of recombinant monoclonal antibody <i>N</i> -glycosylation in GS-NSO cells," <i>Biotechnol Bioeng</i> 75:239-251, 2001.
	Kadoya, Toshihiko, Experiment Report, document D12 of European Opposition EP 1 036 179; September 28, 2004 (translation).
	Nyberg, G. B. et al., "Metabolic effects on recombinant interferon- γ glycosylation in continuous culture of Chinese hamster ovary cells," <i>Biotechnol Bioeng</i> 62(3):336-347, 1999.
	Nyberg, G. B., "Glycosylation site occupancy heterogeneity in Chinese hamster ovary cell culture," Ph.D. Thesis, Massachusetts Institute of Technology, 1998.

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.